Menu
Search
|

Menu

Close
X

Aurobindo Pharma Ltd ARBN.NS (National Stock Exchange of India)

601.90 INR
+15.05 (+2.56%)
As of Feb 23
chart
Previous Close 586.85
Open 589.00
Volume 5,799,249
3m Avg Volume 2,350,495
Today’s High 612.00
Today’s Low 588.05
52 Week High 809.45
52 Week Low 503.05
Shares Outstanding (mil) 585.88
Market Capitalization (mil) 437,068.31
Forward P/E 19.51
Dividend (Yield %) 1.25 ( 0.52 )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.70 Mean rating from 33 analysts

KEY STATS

Revenue (mm, INR)
FY18
124,508
FY17
150,898
FY16
139,552
FY15
150,316
EPS (INR)
FY18
32.343
FY17
39.380
FY16
34.652
FY15
34.111
*Note: Units in Millions of Rupee
**Note: Units in Rupee

KEY RATIOS

Price to Earnings (TTM)
vs sector
19.51
32.90
Price to Sales (TTM)
vs sector
2.91
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
16.26
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

K. Ragunathan
Non-Executive Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
K. Nityananda Reddy
Whole-Time Vice Chairman of the Board, Since 2012
Salary: Rs12,340,000.00
Bonus: --
Santhanam Subramanian
Chief Financial Officer, Since 2014
Salary: Rs8,780,000.00
Bonus: --
B. Adi Reddy
Compliance Officer, Company Secretary, Since 2016
Salary: Rs2,470,000.00
Bonus: --
N. Govindarajan
Managing Director, Executive Director, Since 2012
Salary: Rs20,980,000.00
Bonus: Rs65,000,000.00

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

Water Mark Building,, Plot No. 1
Survey no.9, Kondapur, Hitech Ci
Hyderabad,Telangana
HYDERABAD     500084

Phone: +9140.66725000

Aurobindo Pharma Limited is a pharmaceutical company. The Company is engaged in producing oral and injectable generic formulations and active pharmaceutical ingredients (APIs). Its product portfolio is spread over seven therapeutic/product areas, including antibiotics, anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, anti-allergies and anti-diabetics. It is engaged in developing a range of oncology and hormonal products. It is also developing inhalation and dermatology products, such as pressurized metered-dose inhaler (pMDI). It markets its products through chain stores in the United States. It has developed over three injectable penem products. The Company, through its subsidiary, manufactures and sells nutritional supplements. It has over 10 manufacturing units and approximately two research and development centers. The Company, in addition to marketing its products domestically, also markets its products globally in over 150 countries.

SPONSORED STORIES